NCT01598948View on ClinicalTrials.gov

Effect of Mipomersen on LDL-Cholesterol Levels in Patients Treated by Regular Apheresis

PHASE3CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

May 31, 2015

Study Completion Date

June 30, 2015

Conditions
AtherosclerosisLDL-hypercholesterolemia
Interventions
DRUG

mipomersen

mipomersen 200 mg subcutaneously every week for 37 weeks (phase 1: 26 weeks; phase 2: 11 weeks)

Trial Locations (1)

81377

University Munich, Munich

All Listed Sponsors
lead

Ludwig-Maximilians - University of Munich

OTHER

NCT01598948 - Effect of Mipomersen on LDL-Cholesterol Levels in Patients Treated by Regular Apheresis | Biotech Hunter | Biotech Hunter